Cytogen Initiates Clinical Development of Proprietary PSMA Antibody

Cytogen, a product-driven biopharmaceutical company, has announced a new clinical development initiative for a targeted oncology product designed to treat prostate and other cancers.

The product candidate uses DOTA-based bifunctional chelant technology to radiolabel Cytogen's proprietary monoclonal antibody to prostate-specific membrane antigen with a therapeutic radionuclide.